Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Deciphera Pharmaceuticals, Inc. (DCPH)  
$25.36 0.01 (0.04%) as of 4:30 Fri 5/10


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 60,930,000
Market Cap: 1.55(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $10.11 - $25.38
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to improve the lives of people with cancer. QINLOCK, Co.'s switch-control kinase inhibitor, was developed using Co.'s proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor. In addition, Co. has identified and developed various product candidates from its platform into clinical studies, including vimseltinib and DCC-3116. Co. is studying vimseltinib in a Phase 3 study in patients with tenosynovial giant cell tumor. DCC-3116 is designed to inhibit autophagy, a key tumor survival mechanism in cancer cells.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 10,000 1,687,666
Total Buy Value $0 $0 $138,828 $30,291,232
Total People Bought 0 0 1 3
Total Buy Transactions 0 0 1 3
Total Shares Sold 10,159 75,715 115,161 179,650
Total Sell Value $158,659 $1,108,986 $1,602,723 $2,646,007
Total People Sold 4 5 6 6
Total Sell Transactions 4 14 25 43
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 290
  Page 2 of 12  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Martin Daniel C. Chief Commercial Officer   •       –      –    2023-11-30 4 S $12.57 $223,755 D/D (17,801) 45,435 -23%     
   Hoerter Steven L. President and CEO   •       •      –    2023-10-30 4 S $12.02 $259,256 D/D (21,573) 40,927 -39%     
   Sherman Matthew L EVP & Chief Medical Officer   •       –      –    2023-10-30 4 S $12.02 $28,362 D/D (2,360) 90,628 -39%     
   Pitman Jama See Remarks   •       –      –    2023-10-30 4 S $12.02 $16,909 D/D (1,407) 48,283 -39%     
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2023-10-30 4 S $12.02 $27,833 D/D (2,316) 63,068 -39%     
   Martin Daniel C. Chief Commercial Officer   •       –      –    2023-10-30 4 S $12.02 $16,909 D/D (1,407) 62,884 -39%     
   Hoerter Steven L. President and CEO   •       •      –    2023-10-28 4 A $0.00 $0 D/D 62,500 62,500     -
   Sherman Matthew L EVP & Chief Medical Officer   •       –      –    2023-10-28 4 A $0.00 $0 D/D 8,244 92,988     -
   Pitman Jama See Remarks   •       –      –    2023-10-28 4 A $0.00 $0 D/D 5,576 49,690     -
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2023-10-28 4 A $0.00 $0 D/D 8,244 65,384     -
   Martin Daniel C. Chief Commercial Officer   •       –      –    2023-10-28 4 A $0.00 $0 D/D 5,576 64,291     -
   Sherman Matthew L EVP & Chief Medical Officer   •       –      –    2023-10-02 4 S $12.68 $37,305 D/D (2,942) 84,744 -25%     
   Dhanak Dashyant EVP & Chief Scientific Officer   •       –      –    2023-09-15 4 A $0.00 $0 D/D 140,900 140,900     -
   Sherman Matthew L EVP & Chief Medical Officer   •       –      –    2023-06-16 4 S $14.40 $23,835 D/D (1,655) 87,686 30%     
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2023-06-16 4 S $14.40 $23,835 D/D (1,655) 57,158 30%     
   Martin Daniel C. Chief Commercial Officer   •       –      –    2023-06-16 4 S $14.40 $17,829 D/D (1,238) 58,413 30%     
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2023-06-16 4 S $14.40 $23,835 D/D (1,655) 57,140 30%     
   Pitman Jama See Remarks   •       –      –    2023-06-16 4 S $14.40 $17,829 D/D (1,238) 43,812 30%     
   Friedman Franklin Stuart Director   –       •      –    2023-06-08 4 B $13.88 $138,828 D/D 10,000 10,000 2.39 -24%     
   Walsh Dennis Leo Director   –       •      –    2023-05-10 4 B $13.86 $152,416 D/D 11,000 11,000 2.39 2%     
   Hoerter Steven L. President and CEO   •       •      –    2023-03-21 4 AS $15.57 $116,782 D/D (7,500) 0 -12%     
   Brightstar Associates Llc 10% Owner   –       –       •   2023-02-28 4 OE $0.01 $24,277 D/D 2,427,693 22,145,707     -
   Pitman Jama See Remarks   •       –      –    2023-02-16 4 S $15.10 $17,500 D/D (1,159) 45,050 5%     
   Martin Daniel C. Chief Commercial Officer   •       –      –    2023-02-16 4 S $15.10 $17,500 D/D (1,159) 58,381 5%     
   Sherman Matthew L EVP & Chief Medical Officer   •       –      –    2023-02-16 4 S $15.10 $14,661 D/D (971) 88,145 5%     
  290 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 2 of 12
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us